ProPublica

Journalism in the Public Interest

Cancel

Prescriber Checkup

At A Glance: This Prescriber in 2012

Family Medicine

Self-Reported Primary Specialty

See Other Prescribers With This Specialty in This State »

12,124Medicare Part D Prescriptions Filled, Including Refills

Rank: 329 out of 4623

$470K Total Retail Price of All Prescriptions

Rank: 834 out of 4623

414 Patients Receiving at Least One Drug in Part D
79%Patients 65 Years and Older
50% Subsidized Claims for Low-Income Patients

How Does This Prescriber Compare to Peers?

In the same specialty and state. Caveats »

Drugs That Present Special Risks
Costs of Prescribing
Higher avg Average for
this specialty
in Texas
Lower avg

Schedule Two
Controlled Substances

N/A

Schedule Three
Controlled Substances

27% of this provider’s 414 patients filled at least one prescription for a schedule three drug, compared to an average of 14%.

Risky Drugs to Seniors

2% of this provider’s 9,509 prescriptions for patients 65 and older were for "potentially dangerous" drugs, compared to an average of 2%.

Brand Name Drugs

21% of this provider’s prescriptions were for brand-name drugs, compared to an average of 25%.

Prescription Price

$39 was the average price of a prescription from this provider, compared to $61 among peers.

Prescriptions per Patient

29 is the average number of prescriptions (including refills) per patient, compared to an average of 17.


Another View

This chart shows a different comparison of all providers in this specialty based on their mix of drugs and volume. Providers are grouped by similarity; those least like their peers are farthest to the right. Hover over the bars to see names of other prescribers.

← Prescribers more like their peers Prescribers less like their peers →
KEY: How to read this
chart

Fewer Prescribers
More Prescribers

This Prescriber
Hover to see more prescribers

This Prescriber's Drugs

The table below list this provider’s drugs, the number of prescriptions and how many went to seniors. Drugs are ranked by volume and compared with the rank for all providers in the same specialty and state.

Click to Filter by Category

Clear Filter


S2

A schedule two drug. More » Schedule two drugs have a high potential for abuse and severe dependence, according to the Drug Enforcement Administration.

S3

A schedule three drug. More » Schedule three drugs have potential for abuse and dependence, according to the Drug Enforcement Administration.

A

An antipsychotic drug. More » Antipsychotics are frequently given to dementia patients, though it increases their risk of death.

R

A risky drug for seniors. More » The American Geriatrics Society has said this drug is "potentially dangerous" for seniors and might be inappropriate.

10

This provider is among the top 10 prescribers of
this drug in the country.

This provider’s prescriptions for this drug were for more days than those of peers. More » Because of this, his or her prescription count may be lower.

This provider’s prescriptions for this drug were for fewer days than those of peers. More » Because of this, his or her prescription count may be higher.

This Drug's Rank
Drug Name Total Prescriptions Filled
Including Refills
Prescriptions
to 65+
Category For this Prescriber For All Prescribers in
This Specialty in Texas
HYDROCODONE-ACETAMINOPHEN 630 427 S3 1 3
LEVOTHYROXINE SODIUM 577 524 2 1
SIMVASTATIN 497 451 3 2
LISINOPRIL 480 401 4 4
FUROSEMIDE 385 331 5 8
OMEPRAZOLE 338 292 6 7
METFORMIN HCL 331 242 7 6
METOPROLOL TARTRATE 330 253 8 9
POTASSIUM CHLORIDE 320 260 9 14
CITALOPRAM HBR 231 209 10 23
AMLODIPINE BESYLATE 230 208 11 5
METOPROLOL SUCCINATE 220 183 12 13
PRAVASTATIN SODIUM 211 179 13 11
GLIMEPIRIDE 193 140 14 38
GABAPENTIN 185 151 15 16
LOSARTAN POTASSIUM 183 154 16 21
WARFARIN SODIUM 163 138 17 24
HYDROCHLOROTHIAZIDE 157 122 18 10
CARVEDILOL 122 104 19 25
ALLOPURINOL 115 103 20 37
TRAMADOL HCL 114 75 21 15
CIPROFLOXACIN HCL 113 93 22 43
ZOLPIDEM TARTRATE 112 90 23 18
LISINOPRIL-HYDROCHLOROTHIAZIDE 111 65 24 19
CLOPIDOGREL 105 88 25 31
SERTRALINE HCL 102 91 26 26
ATORVASTATIN CALCIUM 96 87 27 12
SULFAMETHOXAZOLE-TRIMETHOPRIM 86 47 28 68
LANTUS 79 62 29 44
PLAVIX 78 72 30 45
PREDNISONE 78 53 30 50
LEVOFLOXACIN 76 50 32 81
CARISOPRODOL 75 28 R 33 71
MIRTAZAPINE 75 73 33 57
MELOXICAM 74 53 35 27
ATENOLOL 72 33 36 28
NEXIUM 71 36 37 17
FLUOXETINE HCL 65 36 38 61
DIGOXIN 65 65 38 58
LOSARTAN-HYDROCHLOROTHIAZIDE 59 56 40 46
TERAZOSIN HCL 59 45 40 143
DOXYCYCLINE HYCLATE 58 49 42 101
OXYBUTYNIN CHLORIDE ER 56 49 43 163
BUSPIRONE HCL 56 55 43 135
TRAZODONE HCL 54 26 45 42
SYNTHROID 54 30 45 73
DONEPEZIL HCL 53 53 47 30
CRESTOR 52 26 48 20
BUPROPION HCL SR 52 15 48 233
NOVOLIN R 51 28 50 113
CARBIDOPA-LEVODOPA 50 50 51 116
About This Data

ProPublica obtained prescribing data from Medicare’s prescription drug benefit, known as Part D, under the Freedom of Information Act. The data for 2012 includes more than 1.2 billion prescriptions written by nearly 1.5 million doctors, nurses and other providers. This database lists about 382,000 of those providers who wrote 50 or more prescriptions for at least one drug that year. Almost three-fourths went to patients 65 and older; the rest were for disabled patients. Methodology »

Incorrect Info?

If you are a provider and you believe your address is incorrect, check the listing you created on the National Provider Identifier registry. If you change your listing, send a note to drugs@propublica.org and we will update your information. If you have other questions about this data, send a note to drugs@propublica.org.

Caveats
  • No comparisons are shown if 10 or fewer prescribers in the state share this specialty.
  • The list of top drugs includes only those for which this provider wrote 50 or more prescriptions, but all prescriptions are counted in the summary totals at the top.
  • The calculation of “Risky Drugs to Seniors” does not include drugs for which a provider wrote 11 or fewer prescriptions because Medicare redacted the information to protect patient privacy.
  • Comparisons do not take into account the medical conditions of patients. Medications for certain conditions do not have generic alternatives, so patients would receive more expensive brand name drugs.
  • This provider's address and specialty information was last updated on May 14, 2008.
  • Comparisons are based on each provider’s current address, not necessarily where he or she worked during the time period covered in this database.